Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress
These data were included in two oral presentations at the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually.
- These data were included in two oral presentations at the European Renal Association - European Dialysis Transplant Association (ERA-EDTA) Congress being held May 19-22, 2022 in Paris, France, in person and virtually.
- Dr. Lin continued, We also presented new data from a post-hoc analysis from our double-blind, placebo-controlled Phase 2 study which suggested atacicept has the potential to improve renal function in patients with mild-to-moderate SLE renal disease.
- We anticipate the planned Phase 3 COMPASS clinical trial evaluating atacicept 150 mg to help determine whether atacicept improves renal function in moderate-to-severe lupus nephritis.
- Results from this post-hoc analysis of the Phase 2 trial of atacicept in SLE suggest atacicept may improve renal function in patients with mild-to-moderate SLE renal disease.